WAVE Clinical Platform vs Rapid SDH

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Excel Medical Electronics
VS
by RapidAI (formerly iSchemaView)

AI Verdict

Tool A, the WAVE Clinical Platform, is designed for continuous, general patient surveillance, using predictive algorithms to warn of overall physiological deterioration. In contrast, Tool B, Rapid SDH, is a highly specialized AI module focused on the rapid detection of subdural hematomas from CT scans to accelerate neurocritical care decisions. While both offer FDA-cleared AI for clinical decision support, their distinct focus areas—general patient monitoring versus specific imaging diagnostics—make them adjacent rather than direct competitors.

Choose WAVE Clinical Platform if…

Choose WAVE Clinical Platform if your primary goal is continuous, proactive patient surveillance across multiple units to prevent general patient deterioration. This tool excels at providing early warnings (up to 6 hours in advance) based on predictive analytics of physiological data, enabling timely clinical intervention and enhancing overall patient safety through integrated EMR and mobile alerts.

View WAVE Clinical Platform →

Choose Rapid SDH if…

Choose Rapid SDH if your critical need is the immediate and accurate detection of suspected subdural hematomas from CT scans to expedite neurocritical care decisions. This AI module delivers notifications in under a minute, making it ideal for emergency departments and stroke centers where rapid diagnosis of specific acute neurological conditions is crucial for time-sensitive treatment eligibility and intervention.

View Rapid SDH →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature WAVE Clinical Platform Rapid SDH
Pricing Contact for pricing Contact vendor
Deployment Software platform, leverages existing hospital IT infrastructure, client-server architecture, web-enabled devices. Cloud-based, On-premise
BAA Available Unknown Yes AI-estimated
FDA Status 1 AI-estimated Yes AI-estimated
HIPAA Unknown Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Rapid SDH

Rapid SDH focuses on a highly streamlined and efficient user experience for its specific task, delivering critical notifications in under a minute and integrating seamlessly with existing clinical workflows like PACS, email, and mobile apps. While WAVE Clinical Platform offers comprehensive, continuous monitoring with customizable alarms, Rapid SDH's targeted approach prioritizes rapid and efficient interaction for time-sensitive neurocritical care decisions.

Clinical Value

Rapid SDH

Rapid SDH offers exceptional clinical value through its rapid and highly accurate detection of subdural hematomas, with a 99% positive predictive value and high sensitivity/specificity, enabling accelerated neurocritical care decisions. Its broader platform has also been instrumental in expanding stroke treatment windows in influential trials. While WAVE Clinical Platform demonstrates significant value in predicting general patient deterioration and reducing unexpected deaths, Rapid SDH's precise, time-critical diagnostic capability for a high-stakes condition provides a more immediate and quantifiable impact on specific patient outcomes.

Pricing & Value

Rapid SDH

Neither tool provides transparent pricing, requiring direct vendor contact. However, Rapid SDH explicitly states its HIPAA compliance and the availability of a Business Associate Agreement (BAA) in its structured facts. This upfront transparency regarding crucial compliance aspects adds significant value and reduces uncertainty for potential buyers compared to WAVE Clinical Platform, which requires contacting the vendor for these details.

Enterprise Readiness

Rapid SDH

Rapid SDH demonstrates strong enterprise readiness by offering flexible deployment options (cloud-based and on-premise) and explicitly confirming HIPAA compliance and BAA availability. While WAVE Clinical Platform is FDA-cleared and integrates with EMRs and existing IT infrastructure, Rapid SDH's clear declaration of deployment flexibility and compliance makes it slightly more adaptable and reassuring for diverse enterprise environments.

Innovation

WAVE Clinical Platform

WAVE Clinical Platform stands out as the 'first FDA-cleared AI patient surveillance system' that uses predictive algorithms to provide early warning of patient deterioration up to six hours in advance. This represents a broader, foundational innovation in continuous, proactive patient monitoring. While Rapid SDH's speed and accuracy in detecting subdural hematomas are impressive, the core AI technology for medical image analysis is a more established field.

Support & Docs

Rapid SDH

RapidAI, the company behind Rapid SDH, explicitly offers 24/7/365 customer support globally via email and phone, along with a range of educational resources, guides, and learning materials. In contrast, the provided information for WAVE Clinical Platform does not detail its support structure or documentation availability, making Rapid SDH the clear winner in this dimension due to its transparent and comprehensive support offerings.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature WAVE Clinical Platform Rapid SDH
Name WAVE Clinical Platform Rapid SDH
Company Excel Medical Electronics RapidAI (formerly iSchemaView)
Tagline Predicting the preventableu2122 Where AI meets patient care.
Description The WAVE Clinical Platform by Excel Medical Electronics is the first FDA-cleared AI patient surveillance system that uses predictive algorithms to provide early warning of patient deterioration, integrating with EMRs and mobile devices to enhance clinical decision support and patient safety. Rapid SDH by RapidAI is an FDA-cleared AI module that rapidly detects suspected acute and chronic subdural hematomas on CT scans, delivering notifications in under a minute to accelerate neurocritical care decisions.
Key Features Always-on remote patient monitoring, Near real-time display of physiologic data, waveforms, and alarms, Predictive analytics for patient deterioration (e.g., Visensia Safety Index), Early warning of patient deterioration (up to 6 hours in advance), Integration with Electronic Medical Records (EMR), Mobile device compatibility for alerts and data display, Customizable alarm management and routing (AlarmNavigator), Risk stratification of patients AI-powered detection of suspected hemispheric acute and chronic subdural hematoma (SDH), Notifications to clinicians in one minute or less, High positive predictive value (PPV) of 99% (93% sensitivity, 99% specificity) for SDHs >1ml, Integration with Rapid mobile app, PACS, and email for notifications, Part of a comprehensive hemorrhagic and trauma care AI solution (with Rapid ICH and Rapid Hyperdensity), Analyzes non-contrast CT scans, Aids in streamlining decision-making and expediting patient care, Supports identification of treatment eligibility
Specialties Critical Care, Emergency Medicine, Hospital Medicine Emergency Medicine, Neurosurgery, Radiology

Videos

Demos, reviews, and walkthroughs featuring WAVE Clinical Platform and Rapid SDH.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

The WAVE Clinical Platform is an FDA-cleared AI patient surveillance system that uses predictive algorithms to provide early warning of general patient deterioration. Rapid SDH is an FDA-cleared AI module specifically designed for the rapid detection of suspected acute and chronic subdural hematomas on CT scans to accelerate neurocritical care decisions.
The WAVE Clinical Platform analyzes physiologic data, waveforms, and alarms, integrating with Electronic Medical Records (EMRs) and mobile devices. Rapid SDH analyzes non-contrast CT scans and integrates with the Rapid mobile app, PACS, and email for notifications.
The WAVE Clinical Platform provides early warning of patient deterioration up to 6 hours in advance. Rapid SDH delivers notifications for suspected subdural hematomas in one minute or less.
The WAVE Clinical Platform offers early warning of patient deterioration up to 6 hours in advance. Rapid SDH has a high positive predictive value (PPV) of 99% (93% sensitivity, 99% specificity) for SDHs greater than 1ml.
The WAVE Clinical Platform provides always-on remote patient monitoring and risk stratification for general patient deterioration. Rapid SDH is highly specialized, focusing on AI-powered detection of suspected hemispheric acute and chronic subdural hematomas.
AI Tool Finder
AI-powered search. Results may not be comprehensive.